Table 4.
Patients (n = 9) | Pretreatment | Posttreatment | |||||||
---|---|---|---|---|---|---|---|---|---|
Baseline | 1 week | p value | 3 months | p value | 6 months | p value | 1 year | p value | |
PDQ‐39 | 56.9 ± 11.4 | 41.9 ± 21.5 | .097 | 35.7 ± 18.6 | .021a | 35.5 ± 19.1 | .021a | 35.5 ± 18.8 | .018a |
EQ‐5D | 9.3 ± 1.7 | 7.9 ± 2.6 | .041a | 7.5 ± 2.1 | .026a | 8.2 ± 2.5 | .140 | 7.5 ± 1.9 | .042a |
EQ‐VAS | 54.9 ± 11.7 | 71.7 ± 6.9 | .017a | 68.7 ± 7.7 | .027a | 64.3 ± 13.6 | .249 | 66.2 ± 9.9 | .068 |
ZBI | 30.9 ± 17.7 | 26.0 ± 17.8 | .173 | 22.2 ± 10.8 | .042a | 27.5 ± 16.2 | .074 | 27.7 ± 15.5 | .058 |
Results in mean ± standard deviation.
PDQ‐39, quality‐of‐life questionnaire in PD—39 items; EQ‐5D, European Quality of life—5 dimensions; EQ‐VAS, European quality‐of‐life Visual Analogue Scale; ZBI, Zarit Burden Index.
p < .05 indicate significant differences compared to baseline.